In May 2021, the Health Sciences Authority (HSA) approved the use of Romosozumab (Evenity), a novel biologic, for the treatment osteoporosis in postmenopausal women at high risk of fractures. Fragility fractures are common amongst postmenopausal . . .
Sign Up or Log In as a healthcare professional to read the full article.